Bone Marrow Transplant Clinical Network

描述(由申请人提供)：宾夕法尼亚大学阿布拉姆森癌症中心(ACC)的骨髓和干细胞移植计划(BMSCTP)是美国最大和最古老的计划之一。这项积极的计划接受所有年龄、性别和种族血统的患者，并进行各种形式的干细胞移植，包括自体、异基因、非清髓性和脐带血，匹配和不匹配，与无数疾病相关和无关。Edward Stadtmauer博士一直是该BMT CTN核心临床中心的PI，也是ACC血液恶性肿瘤项目的联合负责人，因此，患者可以直接获得BMT CTN临床试验，这已经反映在我们中心令人印象深刻的收益中。David Porter博士与Stadtmauer博士密切合作，担任异基因骨髓移植和免疫疗法主任已有14年之久。从宾夕法尼亚大学到BMT CTN中心已经积累了210名患者；在任何单一中心中，积累的患者数量位居第三。宾夕法尼亚大学的调查人员在该网络中表现出了智慧的领导力；是6个礼宾小组的成员(2人担任研究主席)，并担任3个委员会的主席。宾夕法尼亚大学的研究人员是非常成功的骨髓瘤系列临床试验的关键。ACC在所有3项试验中均领先于应计，所有试验均由方案团队领导。宾夕法尼亚大学的BMSCTP一直非常活跃，2009年进行了205例干细胞移植；125例自体干细胞移植，80例异体干细胞移植。BMSCTP得到了许多ACC世界级研究资源的支持：我们的研究提案“在低强度异基因干细胞移植后，使用或不使用马拉韦罗(CCR5抑制剂)作为GVHD预防药物的他克莫司/MTX的III期试验”被选为宾夕法尼亚大学的许多替代方案，以展示我们的专长领域，该方案基于我们自己的先导性研究工作，满足了一项重大临床需求，即通过降低GVHD来改善异基因造血干细胞移植的结果，并且可以及时完成。这些强大的临床研究、患者护理、该领域的思想领袖以及BMT CTN试验中有据可查的热情和成功的这些属性，使我们的中心能够促进新治疗方法和策略的有效比较，从而造福于血液或骨髓移植。

DESCRIPTION (provided by applicant): This Bone Marrow and Stem Cell Transplant Program (BMSCTP) of the University of Pennsylvania Abramson Cancer Center (ACC) is among the largest and oldest in the nation. This active program sees patients of all ages, sexes and ethnic origins and conducts all forms of stem cell transplantation including autologous, allogeneic, non-myeloablative and cord blood, matched and mismatched, related and unrelated for a myriad of diseases. Dr. Edward Stadtmauer has been the PI of this BMT CTN Core Clinical Center and is also the Co-leader of the ACC Hematologic Malignancies Program and so access to patients for BMT CTN clinical trials is straightforward and this has been reflected in the impressive accrual from our center. Dr David Porter works very closely with Dr Stadtmauer and has been the Director of Allogeneic Bone Marrow Transplant and Immunotherapy for 14 years. 210 patients have been accrued from Penn to BMT CTN; the 3rd largest accrual of any single center. Penn investigators have demonstrated intellectual leadership in the Network; membership on 6 protocol teams (study chairs for 2) and chair of 3 committees. Penn investigators were key to the highly successful myeloma series of clinical trials. ACC led accrual in all 3 trials with protocol team leadership in all. Penn's BMSCTP remains consistently very active with 205 stem cell transplants conducted in 2009; 125 autologous, 80 allogeneic. The BMSCTP is supported by numerous ACC world- class research resources: Our research proposal, "A PHASE III TRIAL OF TACROLIMUS/MTX WITH OR WITHOUT MARAVIROC (A CCR5 INHIBITOR) AS GVHD PROPHYLAXIS AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION" was chosen among many alternatives from Penn to demonstrate an area of our expertise, based on our own pilot study work, fill a major clinical need, namely the improvement of outcome for allogeneic HSCT by reducing GVHD, and can be completed in a timely fashion. These attributes of strong clinical research, patient care, thought leaders in the field and a documented enthusiasm and success in BMT CTN trials uniquely position our Center to promote the efficient comparison of novel treatment methods and strategies to benefit blood or marrow transplantation.